| Literature DB >> 31217471 |
Alejandro Rodríguez-Molinero1, Alexandra Herrero-Larrea2, Antonio Miñarro3, Leire Narvaiza4, César Gálvez-Barrón2, Natalia Gonzalo León5, Esther Valldosera2, Eva de Mingo2, Oscar Macho2, David Aivar2, Efren Pinzón2, Adilis Alba2, Jorge Passarelli2, Nadia Stasi2, Rosa Ana Valverde2, Liane Kruse2, Elisabet Felipe2, Isabel Collado2, Joan Bosch Sabater6.
Abstract
Association between spatial gait parameters and adverse health outcomes in the elderly has not been sufficiently studied. The goal of this study is to evaluate whether the stride length or the step width predict falls, functional loss and mortality. We conducted a prospective cohort study on a probabilistic sample of 431 noninstitutionalized, older-than-64-years subjects living in Spain, who were followed-up for five years. In the baseline visit, spatial gait parameters were recorded along with several control variables, with special emphasis on known medical conditions, strength, balance and functional and cognitive capacities. In the follow-up calls, vital status, functional status and number of falls from last control were recorded. We found that a normalized-to-height stride length shorter than 0.52 predicted recurrent falls in the next 6 months with 93% sensitivity and 53% specificity (AUC: 0.72), and in the next 12 months with 81% sensitivity and 57% specificity (AUC: 0.67). A normalized stride length <0.5 predicted functional loss at 12 months with a sensitivity of 79.4% and specificity of 65.6% (AUC: 0.75). This predictive capacity remained independent after correcting for the rest of risk factors studied. Step-with was not clearly related to functional loss or falls. Both shorter normalized stride length (OR1.56; AUC: 0.62; p < 0.05) and larger step width (OR1.42; AUC: 0.62; p < 0.05) were associated with risk of death at 60 months; however, none of them remained as independent predictor of death, after correcting for other risk factors. In summary, spatial gait parameters may be risk markers for adverse outcomes in the elderly. Step length is independently associated with functional loss and falls at one year, after correction for numerous known risk factors.Entities:
Mesh:
Year: 2019 PMID: 31217471 PMCID: PMC6584504 DOI: 10.1038/s41598-019-45113-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Sample flow chart.
Socio-demographic and health data of participants who completed the first follow-up period.
| Mean | SD | |
|---|---|---|
| 75.8 | 7 | |
| 159.5 | 8.9 | |
| 28.9 | 4.6 | |
| 89.3 | 25.8 | |
| 10.2 | 4.1 | |
|
|
| |
|
| 3 | 3 |
|
| 4 | 4 |
|
|
| |
|
| ||
| Male | 158 | 42.7 |
| Female | 211 | 57.3 |
|
| ||
| None | 92 | 25 |
| Basic | 207 | 56.4 |
| Intermediate | 39 | 10.6 |
| University | 29 | 7.9 |
|
| ||
| Lives alone | 96 | 26.3 |
| Cohabitates with someone | 269 | 73.7 |
|
| ||
| 0 | 293 | 79.3 |
| 01-Feb | 71 | 19.1 |
| 03-Apr | 2 | 0.6 |
| 05-Jun | 4 | 1 |
|
| ||
| 0–3 | 349 | 94.8 |
| 04-Jul | 17 | 4.6 |
| 08-Oct | 3 | 0.6 |
aNumber of chronic conditions.
bNumber of chronic medications used.
Mean differences in all spatial gait parameters.
| MONTH 6 | MONTH 12 | ||||||
|---|---|---|---|---|---|---|---|
| Fallers* | No Fallers | p | Fallers* | No Fallers | p | ||
| Stride length | Total | 66,2 | 90,9 | < | 74,0 | 91,4 | |
| Male | 67,6 | 103,4 | 68,2 | 104,1 | < | ||
| Female | 65,9 | 81,3 | 73,4 | 81,3 | 0,519 | ||
|
|
|
|
|
|
| ||
| Normalized stride length | Total | 0,43 | 0,57 | < | 0,48 | 0,57 | 0,058 |
| Male | 0,39 | 0,62 | < | 0,40 | 0,63 | < | |
| Female | 0,44 | 0,53 | 0,5 | 0,53 | 0,602 | ||
|
|
|
|
|
|
| ||
| Step width | Total | 11,1 | 10,2 | 0,444 | 10,6 | 10,2 | 0,675 |
| Male | 12,8 | 10,3 | 0,276 | 12,7 | 10,3 | 0,230 | |
| Female | 10,7 | 10,0 | 0,650 | 10,1 | 10,0 | 0,951 | |
|
|
|
|
|
|
| ||
|
| Total | 27,7 | 20,8 | 25,4 | 20,3 | 0,200 | |
| Male | 29,1 | 19,0 | < | 29,0 | 18,5 | < | |
| Female | 27,5 | 22,2 | 0,275 | 24,5 | 21,7 | 0,700 | |
*Faller: 2 or more falls within the studied period.
Bivariated regression analysis and odds ratio of each gait parameter for recurrent falls, and accumulated falls.
| Variable | Estimator | p | OR | IC95% | ||
|---|---|---|---|---|---|---|
| Accumulated falls (6 months) | Normalized stride length | −0,43 | < | 0,65 | 0,53 | 0,79 |
| Step width | 0,10 | 0,311 | 1,10 | 0,92 | 1,32 | |
| Ratio width to normalized length | 0,03 | < | 1,03 | 1,00 | 1,06 | |
| Accumulated falls (12 months) | Normalized stride length | −4,57 | < | 0,63 | 0,51 | 0,79 |
| Step width | 0,09 | 0,31 | 1,10 | 0,92 | 1,31 | |
| Ratio width to normalized length | 0,03 | < | 1,03 | 1,00 | 1,06 | |
| Recurrent falls* (6 months) | Normalized stride length | −0,61 | < | 0,54 | 0,41 | 0,71 |
| Step width | 0,05 | 0,419 | 1,05 | 0,93 | 1,19 | |
| Ratio width to normalized length | 0,03 | 1,03 | 1,00 | 1,05 | ||
| Recurrent falls* (12 months) | Normalized stride length | −0,45 | 0,076 | 0,64 | 0,39 | 1,05 |
| Step width | 0,03 | 0,666 | 1,03 | 0,91 | 1,16 | |
| Ratio width to normalized length | 0,02 | 0,092 | 1,02 | 1,00 | 1,05 | |
*Recurrent falls: two or more falls in a given period.
Bold type: significant finding.
Risk of falls, functional decline and dependency associated to different normalized stride length values.
| Normalized stride length | % of fallersa | % functional lossb | % incident disabilityc | |
|---|---|---|---|---|
| Month 6 | Month 12 | Month 12 | Month 12 | |
| 0,16 | 29,5 | 26,9 | 44,9 | 67,8 |
| 0,25 | 19,6 | 19,9 | 32,5 | 59,2 |
| 0,33 | 12,5 | 14,4 | 22,2 | 50 |
| 0,42 | 7,7 | 10,2 | 14,5 | 40,9 |
| 0,51 | 4,6 | 7,1 | 9,1 | 32,3 |
| 0,60 | 2,7 | 4,9 | 5,6 | 24,7 |
| 0,69 | 1,6 | 3,4 | 3,4 | 18,5 |
| 0,77 | 1,0 | 2,3 | 2 | 13,5 |
| 0,86 | 0,6 | 1,6 | 1,2 | 9,7 |
| 0,95 | 0,3 | 1,1 | 0,7 | 6,9 |
aFaller: two or more falls in the studied period.
bFunctional loss: change in Katz index from baseline.
cIncident disability: new dependency from any ABVD (any increment in Katz index from 0).
Final multivariate adjusted models for recurrent falls prediction.
| Estimator | p | exp(coefic) | IC95% | ||
|---|---|---|---|---|---|
|
| |||||
| Normalized stride length | −8,65 | 0,00 | 0,00 | 0,03 | |
| Strength | 0,23 | 1,26 | 1,05 | 1,50 | |
| Cognition (Pfeiffer) | 0,99 | 2,68 | 1,78 | 4,04 | |
| Depression (GDS5) | −1,17 | 0,31 | 0,14 | 0,72 | |
| Comorbidity | −0,73 | 0,48 | 0,26 | 0,89 | |
| Polypharmacy | 0,50 | 1,65 | 1,21 | 2,24 | |
|
| |||||
| Ratio width to length | 0.93 | 2,52 | 1,26 | 5,05 | |
| Cognition (Pfeiffer) | 1,04 | 2,82 | 1,75 | 4,53 | |
| Depression (GDS5) | −0.72 | 0,49 | 0,24 | 0,98 | |
| Comorbidity | −0,71 | 0,50 | 0,27 | 0,90 | |
| Polypharmacy | 0,42 | 1,52 | 1,16 | 1,98 | |
Bold type: significant finding.
Bivariate and multivariate analysis on the predictive capacity of normalized stride length and other basal variables on functional loss.
| Bivariate Analysis | Final Adjusted Model | ||||||
|---|---|---|---|---|---|---|---|
| Estimator | IC95% | T statistic | P | Estimator | IC95% | P | |
| Normalized stride length | −1.72 | −2.50; −0.94 | — | <0.001 | −1.27 | −2.01; −0.54 | 0.001 |
| Sex | −0.21 | −0.40; −0.02 | −2.19 | 0.030 | — | — | — |
| Age | 0.04 | 0.03; 0.05 | 5.35 | <0.001 | 0.03 | 0.02; 0.05 | <0.001 |
| Body Mass Index | 0.01 | 0.02; 0.03 | 0.54 | 0.588 | — | — | — |
| Strength | −0.03 | 0.07; 0.01 | −1.60 | 0.110 | — | — | — |
| Balance | −0.13 | −0.24; −0.01 | −2.15 | 0.033 | — | — | — |
| Functional ability (Katz) | −0.18 | −0.31; −0.07 | −2.66 | 0.008 | −0.35 | −0.50; −0.20 | <0.001 |
| Cognition (Pfeiffer) | 0.08 | −0.01; 0.17 | 1.70 | 0.091 | — | — | — |
| Depression (GDS5) | 0.13 | 0.04; 0.22 | 2.77 | 0.006 | — | — | — |
| Comorbidity | 0.02 | −0.05; 0.08 | 0.50 | 0.620 | — | — | — |
| Polypharmacy | 0.08 | 0.03; 0.12 | 3.50 | 0.001 | 0.04 | 0.00; 0.08 | 0.046 |
| Previous falls | 0.19 | −0.06; 0.44 | 1.48 | 0.141 | — | — | — |